Taking stock of the drug industry, from the lab to the medicine chestMarch 18, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer APStock STAT+ | FTC highlights new concern over 'pay-to-delay' deals that determine when generics are sold "Quantity restrictions, if they are sufficiently strict, have the potential to alter the competitive dynamics of the market," the FTC wrote. By Ed Silverman STAT+ | Small vaccine maker names Operation Warp Speed leader as chairman, raises $110 million Curevo Vaccine is at work on a shingles vaccine designed to have lower rates of side effects than the current shot. By Matthew Herper STAT+ | U.K. plan to require drugmakers to pay higher rebates draws criticism from industry group The U.K. government argued that not proceeding with the proposed changes "risks the integrity and stability" of both rebate programs. By Ed Silverman Sebastian Scheiner/AP STAT+ | Purified T cell transplant lowers risk of immune reaction for blood cancer patients, study shows Privately hold Orca Bio intends to seek approval from the Food and Drug Administration for the off-the-shelf therapy. By Adam Feuerstein STAT+ | New Stanford tool evaluates AI models on tasks that actually matter in health care Stanford researchers have devised a new way to evaluate how well out-of-the-box AI language models perform routine health care tasks. By Brittany Trang More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments